Published Studies Related to Boniva Injection (Ibandronic Acid)
Well-designed clinical trials related to Boniva Injection (Ibandronic Acid)
Long-term safety of intravenous ibandronic acid for up to 4 years in metastatic breast cancer: an open-label trial. [2006]
Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). [2005.12]
Well-designed clinical trials possibly related to Boniva Injection (Ibandronic Acid)
Treatment of reduced bone density with ibandronate in dialysis patients. [2008.07]
Renal safety profiles of ibandronate 6 mg infused over 15 and 60 min: a randomized, open-label study. [2008.07]
Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: A randomized, crossover study (BALTO II). [2008.05]
Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. [2008.03]
Bone turnover and bone collagen maturation in osteoporosis: effects of antiresorptive therapies. [2008.03]
Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study. [2008.01]
Cost effectiveness of ibandronate for the prevention of fractures in inflammatory bowel disease-related osteoporosis: cost-utility analysis using a Markov model. [2008]
Local peroperative treatment with a bisphosphonate improves the fixation of total knee prostheses: a randomized, double-blind radiostereometric study of 50 patients. [2007.12]
Ibandronate is effective in preventing skeletal events in patients with bone metastases from colorectal cancer. [2007.11]
Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases. [2007.07]
Rinsing morcellised bone grafts with bisphosphonate solution prevents their resorption. A prospective randomised double-blinded study. [2006.08]
Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. [2006.08]
Intravenous ibandronate does not affect time to renal function deterioration in patients with skeletal metastases from breast cancer: phase III trial results. [2006.07]
Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. [2006.06]
Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. [2006.05]
Modeling of serum C-telopeptide levels with daily and monthly oral ibandronate in humans. [2006.04]
Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen. [2006.04]
Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2, and 3 years in postmenopausal women with osteoporosis. [2005.11]
Safety and tolerability of oral daily and intermittent ibandronate are not influenced by age. [2005.10]
Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: results from the monthly oral pilot study. [2005.09]
Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. [2005.08]
Efficacy and safety of intravenous bisphosphonates for patients with breast cancer metastatic to bone: a review of randomized, double-blind, phase III trials. [2005.06]
Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE. [2005.03]
Effective doses of ibandronate do not influence the 3-year progression of aortic calcification in elderly osteoporotic women. [2005.02]
[Ibandronate as a new therapeutic agent for osteoporosis.] [2005.01]
Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. [2004.10]
Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. [2004.10]
Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. [2004.08]
Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. [2004.07]
Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. [2004.05]
Efficacy and safety of ibandronate given by intravenous injection once every 3 months. [2004.05]
Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial. [2004.05]
Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. [2004.03.22]
Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study. [2004.03]
Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis. [2004.01]
Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women. [2003.10]
Efficacy and safety of oral weekly ibandronate in the treatment of postmenopausal osteoporosis. [2003.10]
Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. [2003.09]
Oral weekly ibandronate prevents bone loss in postmenopausal women. [2003.08]
Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate. [2003.08]
Dose dependent effects on bone resorption and formation of intermittently administered intravenous ibandronate. [2003.07]
Oral ibandronate: changes in markers of bone turnover during adequately dosed continuous and weekly therapy and during different suboptimally dosed treatment regimens. [2003.06]
The efficacy of 48-week oral ibandronate treatment in postmenopausal osteoporosis when taken 30 versus 60 minutes before breakfast. [2003.04]
Therapy of osteoporosis in patients with Crohn's disease: a randomized study comparing sodium fluoride and ibandronate. [2003.03.15]
Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myeloma. [2003.01]
Effect of bisphosphonates on cartilage turnover assessed with a newly developed assay for collagen type II degradation products. [2002.06]
Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma. [2002.05.01]
Association between pharmacokinetics of oral ibandronate and clinical response in bone mass and bone turnover in women with postmenopausal osteoporosis. [2002.01]
Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis. [2001.10]
Effect of ibandronate on bone loss and renal function after kidney transplantation. [2001.07]
Short- and long-term effects of ibandronate treatment on bone turnover in Paget disease of bone. [2000.05]
Serum parathyroid hormone-related protein levels and response to bisphosphonate treatment in hypercalcemia of malignancy. [1999.10]
Double-blind, randomised, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease. [1999.03]
Bone densitometry: a new, highly responsive region of interest in the distal forearm to monitor the effect of osteoporosis treatment. [1999]
Clinical evaluation of the Serum CrossLaps One Step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptides. [1998.11]
Changes in biochemical markers and bone mass after withdrawal of ibandronate treatment: prediction of bone mass changes during treatment. [1998.05]
Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. [1997.10]
Implementation of an osteoporosis research program with a mobile dual-energy X-ray absorptiometry unit: the Montana/Wyoming experience. [1997]
Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia. [1997]
The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dose-finding study. [1996.11]
Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy. [1996.01]
Other research related to Boniva Injection (Ibandronic Acid)
Oral versus intravenous ibandronic acid: a comparison of treatment options for metastatic bone disease. [2008.12]
Oral versus intravenous ibandronic acid: a comparison of treatment options for metastatic bone disease. [2008.05.27]
Eletriptan: a review of its use in the acute treatment of migraine. [2006]
Oral ibandronic acid. [2005.02]
Renal safety of intravenous ibandronic Acid in breast cancer patients with metastatic bone disease. [2003]
Other possibly related research studies
Use of intravenous bisphosphonates in osteoporosis. [2007.03]
The bisphosphonate ibandronate accelerates osseointegration of hydroxyapatite-coated cementless implants in an animal model. [2007.01]
[Therapeutic agents for disorders of bone and calcium metabolism: Ibandronate] [2007.01]
Population pharmacokinetics of ibandronate in Caucasian and Japanese healthy males and postmenopausal females. [2006.12]
Ibandronate for the treatment of hypercalcemia or nephrocalcinosis in patients with multiple myeloma and acute renal failure: Case reports. [2006]
Intravenous ibandronate: in the treatment of osteoporosis. [2006]
Ibandronate, an experimental intravenous bisphosphonate for osteoporosis, bone metastases, and hypercalcemia of malignancy. [2006.05]
Osseointegration of cementless implants with different bisphosphonate regimens. [2006.06]
Rapid pain relief and remission of sternocostoclavicular hyperostosis after intravenous ibandronate therapy. [2006]
Oral and intravenous ibandronate in the management of postmenopausal osteoporosis: a comprehensive review. [2005]
Effective and rapid treatment of painful localized transient osteoporosis (bone marrow edema) with intravenous ibandronate. [2005.12]
Clinical pharmacology of potent new bisphosphonates for postmenopausal osteoporosis. [2005]
Intermittent ibandronate preserves bone quality and bone strength in the lumbar spine after 16 months of treatment in the ovariectomized cynomolgus monkey. [2004.11]
Rapid administration of ibandronate does not affect renal functioning: evidence from clinical studies in metastatic bone disease and hypercalcaemia of malignancy. [2004.12]
Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease: a pilot study. [2004.09.01]
Ibandronate: a clinical pharmacological and pharmacokinetic update. [2004.09]
Ibandronate: new options in the treatment of osteoporosis. [2003.11]
Intravenous ibandronate in men with osteoporosis: an open pilot study over 2 years. [2003.08]
Injectable bisphosphonates in the treatment of postmenopausal osteoporosis. [2003.08]
Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study. [2003.10]
The effects of three-month intravenous ibandronate on bone mineral density and bone remodeling in Klinefelter's syndrome: the influence of vitamin D deficiency and hormonal status. [2003.10]
Site-specific human breast cancer (MDA-MB-231) metastases in nude rats: model characterisation and in vivo effects of ibandronate on tumour growth. [2003.11.10]
The renal effects of minimally nephrotoxic doses of ibandronate and zoledronate following single and intermittent intravenous administration in rats. [2003.09.30]
Ibandronate: a potent new bisphosphonate in the management of postmenopausal osteoporosis. [2003.06]
Lytic bone lesions in human neuroblastoma xenograft involve osteoclast recruitment and are inhibited by bisphosphonate. [2003.06.15]
Three-monthly ibandronate bolus injection offers favourable tolerability and sustained efficacy advantage over two years in established corticosteroid-induced osteoporosis. [2003.06]
Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three phase II studies. [2003.01]
Review of ibandronate in the treatment of osteoporosis. [2003.03]
Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys. [2003.01]
Effects of treatment with ibandronate on bone mass, architecture, biomechanical properties, and bone concentration of ibandronate in ovariectomized aged rats. [2002.10]
The amino bisphosphonate ibandronate prevents calciphylaxis in the rat at doses that inhibit bone resorption. [2002.10]
Ibandronate treatment decreases the effects of tumor-associated lesions on bone density and strength in the rat. [2002.01]
The amino bisphosphonate ibandronate prevents vitamin D toxicity and inhibits vitamin D-induced calcification of arteries, cartilage, lungs and kidneys in rats. [2001.11]
|
